Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
BCLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $11.25
Previous CloseN/A
Volume34.73K
Average Volume (3M)34.12K
Market Cap
$7.50M
Enterprise Value$14.77M
Total Cash (Recent Filing)$1.22M
Total Debt (Recent Filing)$9.00K
Price to Earnings (P/E)―
Beta1.96
Next Earnings
May 19, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding6,522,350
10 Day Avg. Volume37,233
30 Day Avg. Volume34,121
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-55.75
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$10.00Price Target Upside769.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Brainstorm Cell Therapeutics News
PremiumCompany Announcements
BrainStorm Cell Therapeutics Reports 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesBrainstorm was able to calculate a median survival time vs. a matched historical control demonstrating a statistically significant improvement by 5.5 months for NurOwn treated patients.
Regulatory SupportChanges to the regulatory landscape seem to support a more favorable environment for NurOwn, with the agency more open to evaluating large datasets and understanding how biomarkers correlate with patient outcomes.
Therapy ValidationThere is increasing traction for MSCs within ALS with 5 groups now targeting ALS, providing additional validation for NurOwn – BrainStorm's proprietary cell therapy platform.
Bears Say
Funding NeedsA substantial amount of capital is expected to be needed to fund the program, which lowers the 12-month price target to $10, from a split-adjusted $30.
---
Ownership Overview
20.15% Insiders
2.23% Mutual Funds
2.66% Other Institutional Investors
74.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $1.05 and its highest was $11.25 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Brainstorm Cell Therapeutics’s market cap is $7.50M.
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is May 19, 2025 which is in 41 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on Mar 31, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.97 by $0.45.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Undervalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 6,522,350 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.97. Following the earnings report the stock price went up 5.882%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
---
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
---
BCLI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant regulatory and strategic advancements, cost reduction measures, and commitment from the leadership team. However, it also acknowledged delays in the Phase 3b trial initiation, financial constraints, and skepticism about NurOwn's efficacy. The company is focused on overcoming these challenges with strategic funding and partnerships.Read More>---
BCLI Stock 12 Month Forecast
Average Price Target
$10.00
▲(769.57% Upside)
Technical Analysis
Best Analysts Covering BCLI
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-69.88%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -69.88% per trade.
---